FDA Approves First Generic Versions of FARXIGA - Top_Thought_Leaders - MDSpire

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

  • By

  • Kathryn Wighton

  • April 7, 2026

  • 2 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Approves First Generic Versions of FARXIGA

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study

Effect of stress-induced hyperglycaemia on clinical outcome in paitients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is associated with cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes